anastrozole has been researched along with Endometrial Neoplasms in 28 studies
Endometrial Neoplasms: Tumors or cancer of ENDOMETRIUM, the mucous lining of the UTERUS. These neoplasms can be benign or malignant. Their classification and grading are based on the various cell types and the percent of undifferentiated cells.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To investigate whether there may be a role for aromatase inhibitors (AIs) in the treatment of endometrial hyperplasia (EH) and endometrial adenocarcinoma (EA) in postmenopausal women, a retrospective study on the effect of aromatase inhibitors (anastrozole or letrozole) was conducted for 16 patients who were not amenable to surgical treatment." | 7.75 | Sustained effect of the aromatase inhibitors anastrozole and letrozole on endometrial thickness in patients with endometrial hyperplasia and endometrial carcinoma. ( Barker, LC; Brand, IR; Crawford, SM, 2009) |
| "Tamoxifen treatment results in a doubling of the risk of endometrial cancer after 1-2 years of treatment and a quadrupling after 5 years." | 6.72 | The ATAC ('Arimidex', Tamoxifen, Alone or in Combination) adjuvant breast cancer trial: first results of the endometrial sub-protocol following 2 years of treatment. ( Bianco, AR; Clack, G; Coibion, M; Duffy, S; Jackson, TL; Lansdown, M; Philips, K; Pollard, S; Wells, M, 2006) |
| "Anastrozole (Arimidex) is an oral nonsteroidal aromatase inhibitor which is active in recurrent breast cancer." | 6.69 | A phase II trial of anastrozole in advanced recurrent or persistent endometrial carcinoma: a Gynecologic Oncology Group study. ( Bell, J; Brunetto, VL; Lee, RB; Rose, PG; VanLe, L; Walker, JL, 2000) |
| "Fulvestrant is a new type of oestrogen receptor antagonist with no agonist effects." | 6.43 | Fulvestrant, a new treatment option for advanced breast cancer: tolerability versus existing agents. ( Abram, P; Vergote, I, 2006) |
| "To investigate whether there may be a role for aromatase inhibitors (AIs) in the treatment of endometrial hyperplasia (EH) and endometrial adenocarcinoma (EA) in postmenopausal women, a retrospective study on the effect of aromatase inhibitors (anastrozole or letrozole) was conducted for 16 patients who were not amenable to surgical treatment." | 3.75 | Sustained effect of the aromatase inhibitors anastrozole and letrozole on endometrial thickness in patients with endometrial hyperplasia and endometrial carcinoma. ( Barker, LC; Brand, IR; Crawford, SM, 2009) |
| "This multicenter, open-label, phase 1/2 randomized clinical trial demonstrated that adding vistusertib to anastrozole improved 8wk-PFR, overall response rate, and PFS for patients with endometrial cancer and had manageable adverse events." | 3.11 | Safety and Efficacy of the mTOR Inhibitor, Vistusertib, Combined With Anastrozole in Patients With Hormone Receptor-Positive Recurrent or Metastatic Endometrial Cancer: The VICTORIA Multicenter, Open-label, Phase 1/2 Randomized Clinical Trial. ( Abdeddaim, C; Arnaud, A; Augereau, P; Bazan, F; Chakiba, C; Chevalier-Place, A; Dalban, C; Diaz, JJ; Fabbro, M; Frenel, JS; Garin, G; Heudel, P; Joly, F; Lancry-Lecomte, L; Marcel, V; Pautier, P; Pérol, D; Ray-Coquard, I; Treilleux, I; You, B, 2022) |
| "Patients with endometrial cancer who consented to participate in the study were randomised to receive anastrozole or placebo for a minimum of 14 days prior to definitive surgery." | 2.78 | Neoadjuvant treatment of endometrial cancer using anastrozole: a randomised pilot study. ( Duffy, SR; Hewitt, MJ; Quinton, ND; Thangavelu, A, 2013) |
| "Tamoxifen treatment results in a doubling of the risk of endometrial cancer after 1-2 years of treatment and a quadrupling after 5 years." | 2.72 | The ATAC ('Arimidex', Tamoxifen, Alone or in Combination) adjuvant breast cancer trial: first results of the endometrial sub-protocol following 2 years of treatment. ( Bianco, AR; Clack, G; Coibion, M; Duffy, S; Jackson, TL; Lansdown, M; Philips, K; Pollard, S; Wells, M, 2006) |
| "Anastrozole (Arimidex) is an oral nonsteroidal aromatase inhibitor which is active in recurrent breast cancer." | 2.69 | A phase II trial of anastrozole in advanced recurrent or persistent endometrial carcinoma: a Gynecologic Oncology Group study. ( Bell, J; Brunetto, VL; Lee, RB; Rose, PG; VanLe, L; Walker, JL, 2000) |
| "Type I endometrial cancer is a common tumor of the female genital tract." | 2.53 | Effectiveness of aromatase inhibitors in the treatment of advanced endometrial adenocarcinoma. ( Babilonti, L; Bogliolo, S; Cassani, C; De Silvestri, A; Dominoni, M; Gaggero, CR; Gardella, B; Musacchi, V; Spinillo, A; Zanellini, F, 2016) |
| "The only alternative to breast cancer screening available in France is surgical prevention by prophylactic mastectomy." | 2.53 | [Hormonotherapy for breast cancer prevention: What about women with genetic predisposition to breast cancer?]. ( Callet, N; Fourme, E; Noguès, C; Reyal, F; Sénéchal, C; Stoppa-Lyonnet, D; This, P, 2016) |
| "Fulvestrant is a new type of oestrogen receptor antagonist with no agonist effects." | 2.43 | Fulvestrant, a new treatment option for advanced breast cancer: tolerability versus existing agents. ( Abram, P; Vergote, I, 2006) |
| " This study provides RiBi-based markers relevant for a better selection of patients with advanced endometrial carcinoma by predicting the response of endocrine therapy combined with mTOR inhibitor." | 1.91 | Ribosome biogenesis-based predictive biomarkers in endocrine therapy (Anastrozole) combined with mTOR inhibitor (Vistusertib) in endometrial cancer: translational study from the VICTORIA trial in collaboration with the GINECO group. ( Abadie-Lacourtoisie, S; Bazan, F; Chabaud, S; Colombe-Vermorel, A; Coquan, E; Dalban, C; Diaz, JJ; Fabbro, M; Frenel, JS; Garin, G; Heudel, PE; Marcel, V; Martinez, S; Mourksi, NE; Odeyer, L; Pérol, D; Ray-Coquard, I; Simioni, V; Tabone-Eglinger, S; Treilleux, I, 2023) |
| "Anastrozole was administered 1 mg daily orally after performing an accurate clinical and radiological staging." | 1.62 | Palliative treatment of endometrial cancer: what is the role of anastrozole in elderly women? ( Bogliolo, S; Carletti, GV; Cassani, C; De Silvestri, A; Dominoni, M; Gardella, B; Spinillo, A, 2021) |
| "Low-grade endometrial stromal sarcoma is very rare and difficult to diagnose in the early stage." | 1.42 | Long-term survival in low-grade endometrial stromal sarcoma with childbirth and multidisciplinary treatment: a case report. ( Horio, M; Ichihara, S; Inoue, T; Ishihara, Y; Ito, M; Kondo, I; Maeda, O; Matsumura, Y; Moritani, S; Sugiyama, K; Yamamoto, S, 2015) |
| "Anastrozole was effective to recurrent low-grade ESS even after being refractory to progestin therapy." | 1.37 | Aromatase inhibitor anastrozole as a second-line hormonal treatment to a recurrent low-grade endometrial stromal sarcoma: a case report. ( Ikeda, Y; Kawana, K; Kozuma, S; Nakagawa, S; Oda, K; Shoji, K; Takazawa, Y; Taketani, Y; Yasugi, T, 2011) |
| "We compared the efficacy of endometrial cancer neoadjuvant treatment in 38 patients receiving nonsteroid (letrozol, anastrozol) or steroid (ekzemestan) aromatase inhibitors and 12 patients receiving metformin." | 1.37 | [Effectiveness of aromatase inhibitors in comparison with metformin for neoadjuvant treatment in patients with endometrial cancer]. ( Bershteĭn, LM; Boiarkina, MP; Danilova, MA; Gershfel'd, ÉD; Khadzhimba, AS; Kovalevskiĭ, AIu; Maksimov, SIa; Meshkova, IE; Turkevich, EA, 2011) |
| "Patients with metastatic endometrial carcinoma may respond to hormonal therapy with progestins." | 1.33 | Durable response of metastatic endometrial carcinoma to treatment with fulvestrant (Faslodex) after prior progestin and anastrozole therapy. ( Hoffman, MA; Khan, A, 2006) |
| "This is the first report of breast carcinoma metastatic to the endometrium in a patient on adjuvant anastrozole therapy." | 1.33 | Lobular carcinoma of the breast metastatic to the uterus in a patient under adjuvant anastrozole therapy. ( Bolat, F; Erkanli, S; Haberal, A; Kayaselcuk, F; Kuscu, E; Sakalli, H, 2006) |
| "Hormonal therapy for endometrial cancer is occasionally warranted in the premenopausal woman who is interested in maintaining fertility." | 1.32 | Anastrozole, an aromatase inhibitor, and medroxyprogesterone acetate therapy in premenopausal obese women with endometrial cancer: a report of two cases successfully treated without hysterectomy. ( Amezcua, C; Bahador, A; Burnett, AF, 2004) |
| "Letrozole was found to be a highly potent inhibitor of tumor proliferation and more effective than tamoxifen." | 1.30 | Preclinical studies using the intratumoral aromatase model for postmenopausal breast cancer. ( Brodie, A; Liu, Y; Long, B; Lu, Q; Wang, JP; Yue, W, 1998) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (3.57) | 18.2507 |
| 2000's | 12 (42.86) | 29.6817 |
| 2010's | 10 (35.71) | 24.3611 |
| 2020's | 5 (17.86) | 2.80 |
| Authors | Studies |
|---|---|
| Heudel, P | 1 |
| Frenel, JS | 2 |
| Dalban, C | 2 |
| Bazan, F | 2 |
| Joly, F | 1 |
| Arnaud, A | 1 |
| Abdeddaim, C | 1 |
| Chevalier-Place, A | 1 |
| Augereau, P | 1 |
| Pautier, P | 1 |
| Chakiba, C | 1 |
| You, B | 1 |
| Lancry-Lecomte, L | 1 |
| Garin, G | 2 |
| Marcel, V | 2 |
| Diaz, JJ | 2 |
| Treilleux, I | 2 |
| Pérol, D | 2 |
| Fabbro, M | 2 |
| Ray-Coquard, I | 2 |
| Mourksi, NE | 1 |
| Colombe-Vermorel, A | 1 |
| Odeyer, L | 1 |
| Simioni, V | 1 |
| Abadie-Lacourtoisie, S | 1 |
| Coquan, E | 1 |
| Martinez, S | 1 |
| Tabone-Eglinger, S | 1 |
| Chabaud, S | 1 |
| Heudel, PE | 1 |
| Gardella, B | 2 |
| Dominoni, M | 2 |
| Bogliolo, S | 2 |
| Cassani, C | 2 |
| Carletti, GV | 1 |
| De Silvestri, A | 2 |
| Spinillo, A | 2 |
| Friedlander, M | 2 |
| Benson, C | 1 |
| O'Connell, RL | 2 |
| Reed, N | 1 |
| Clamp, A | 2 |
| Lord, R | 2 |
| Millan, D | 2 |
| Nottley, S | 2 |
| Amant, F | 2 |
| Steer, C | 1 |
| Anand, A | 1 |
| Mileshkin, L | 2 |
| Beale, P | 2 |
| Banerjee, S | 1 |
| Bradshaw, N | 1 |
| Kelly, C | 1 |
| Carty, K | 2 |
| Divers, L | 1 |
| Alexander, L | 2 |
| Edmondson, R | 2 |
| Yanase, T | 1 |
| Kikuchi, A | 1 |
| Sasagawa, M | 1 |
| Honma, S | 1 |
| Sjoquist, KM | 1 |
| Andrews, J | 1 |
| Jyothirmayi, R | 1 |
| Bonaventura, T | 1 |
| Goh, J | 1 |
| Hall, M | 1 |
| Green, J | 1 |
| Paul, J | 1 |
| Scurry, J | 1 |
| Boccardo, F | 1 |
| Guglielmini, P | 1 |
| Bordonaro, R | 1 |
| Fini, A | 1 |
| Massidda, B | 1 |
| Porpiglia, M | 1 |
| Roagna, R | 1 |
| Serra, P | 1 |
| Orzalesi, L | 1 |
| Ucci, G | 1 |
| Rubagotti, A | 1 |
| Thangavelu, A | 1 |
| Hewitt, MJ | 1 |
| Quinton, ND | 1 |
| Duffy, SR | 1 |
| Maeda, O | 1 |
| Moritani, S | 1 |
| Ichihara, S | 1 |
| Inoue, T | 1 |
| Ishihara, Y | 1 |
| Yamamoto, S | 1 |
| Ito, M | 1 |
| Matsumura, Y | 1 |
| Sugiyama, K | 1 |
| Horio, M | 1 |
| Kondo, I | 1 |
| Musacchi, V | 1 |
| Zanellini, F | 1 |
| Gaggero, CR | 1 |
| Babilonti, L | 1 |
| Sénéchal, C | 1 |
| Reyal, F | 1 |
| Callet, N | 1 |
| This, P | 1 |
| Noguès, C | 1 |
| Stoppa-Lyonnet, D | 1 |
| Fourme, E | 1 |
| Bellone, S | 1 |
| Shah, HR | 1 |
| McKenney, JK | 1 |
| Stone, PJ | 1 |
| Santin, AD | 1 |
| Barker, LC | 1 |
| Brand, IR | 1 |
| Crawford, SM | 1 |
| Bershteĭn, LM | 2 |
| Danilova, MA | 2 |
| Kovalevskiĭ, AIu | 2 |
| Gershfel'd, ED | 2 |
| Poroshina, TE | 1 |
| Tsyrlina, TE | 1 |
| Meshkova, IE | 2 |
| Turkevich, EA | 2 |
| Maksimov, SIa | 2 |
| Shoji, K | 1 |
| Oda, K | 1 |
| Nakagawa, S | 1 |
| Kawana, K | 1 |
| Yasugi, T | 1 |
| Ikeda, Y | 1 |
| Takazawa, Y | 1 |
| Kozuma, S | 1 |
| Taketani, Y | 1 |
| Lisianskaia, AS | 1 |
| Manikhas, GM | 1 |
| Fadeeva, EP | 1 |
| Fedosenko, KV | 1 |
| Tapil'skaia, NI | 1 |
| Boiarkina, MP | 1 |
| Khadzhimba, AS | 1 |
| Leiser, AL | 1 |
| Hamid, AM | 1 |
| Blanchard, R | 1 |
| Burnett, AF | 1 |
| Bahador, A | 1 |
| Amezcua, C | 1 |
| Hiura, M | 1 |
| Oshita, T | 1 |
| Nogawa, T | 1 |
| Yokoyama, T | 1 |
| Duffy, S | 1 |
| Jackson, TL | 1 |
| Lansdown, M | 1 |
| Philips, K | 1 |
| Wells, M | 1 |
| Pollard, S | 1 |
| Clack, G | 1 |
| Coibion, M | 1 |
| Bianco, AR | 1 |
| Vergote, I | 1 |
| Abram, P | 1 |
| Hoffman, MA | 1 |
| Khan, A | 1 |
| Erkanli, S | 1 |
| Kayaselcuk, F | 1 |
| Kuscu, E | 1 |
| Bolat, F | 1 |
| Sakalli, H | 1 |
| Haberal, A | 1 |
| Alkasi, O | 1 |
| Meinhold-Heerlein, I | 1 |
| Zaki, R | 1 |
| Fasching, P | 1 |
| Maass, N | 1 |
| Jonat, W | 1 |
| Beckmann, MW | 1 |
| Brodie, A | 1 |
| Lu, Q | 1 |
| Liu, Y | 1 |
| Long, B | 1 |
| Wang, JP | 1 |
| Yue, W | 1 |
| Rose, PG | 1 |
| Brunetto, VL | 1 |
| VanLe, L | 1 |
| Bell, J | 1 |
| Walker, JL | 1 |
| Lee, RB | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Multicentric, Randomized, Non Comparative, Open-label Phase I/II Evaluating AZD2014 (Dual Mammalian Target of Rapamycin Complex 1/2 (mTORC1/mTORC2) Inhibitor) in Combination With Anastrozole Versus Anastrozole Alone in the Treatment of Metastatic Hormon[NCT02730923] | Phase 1/Phase 2 | 72 participants (Anticipated) | Interventional | 2016-04-30 | Active, not recruiting | ||
| Gonadotropin-releasing Hormone Agonist Combined With Letrozole Compared With Megestrol Acetate or Medroxyprogesterone Acetate Alone as Fertility-sparing Treatment in Early Endometrial Cancer[NCT05247268] | Phase 2 | 104 participants (Anticipated) | Interventional | 2022-03-11 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
4 reviews available for anastrozole and Endometrial Neoplasms
| Article | Year |
|---|---|
Effectiveness of aromatase inhibitors in the treatment of advanced endometrial adenocarcinoma.
Topics: Adenocarcinoma; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Endometria | 2016 |
Effectiveness of aromatase inhibitors in the treatment of advanced endometrial adenocarcinoma.
Topics: Adenocarcinoma; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Endometria | 2016 |
[Hormonotherapy for breast cancer prevention: What about women with genetic predisposition to breast cancer?].
Topics: Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Endometrial Neoplasms; Female; | 2016 |
[Hormonotherapy for breast cancer prevention: What about women with genetic predisposition to breast cancer?].
Topics: Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Endometrial Neoplasms; Female; | 2016 |
[Postoperative hormone (endocrine) therapy in endometrial carcinoma].
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Chemotherapy, Adjuvant; Drug The | 2004 |
[Postoperative hormone (endocrine) therapy in endometrial carcinoma].
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Chemotherapy, Adjuvant; Drug The | 2004 |
Fulvestrant, a new treatment option for advanced breast cancer: tolerability versus existing agents.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms | 2006 |
Fulvestrant, a new treatment option for advanced breast cancer: tolerability versus existing agents.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms | 2006 |
7 trials available for anastrozole and Endometrial Neoplasms
| Article | Year |
|---|---|
Safety and Efficacy of the mTOR Inhibitor, Vistusertib, Combined With Anastrozole in Patients With Hormone Receptor-Positive Recurrent or Metastatic Endometrial Cancer: The VICTORIA Multicenter, Open-label, Phase 1/2 Randomized Clinical Trial.
Topics: Aged; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Breast Neoplasms; End | 2022 |
Safety and Efficacy of the mTOR Inhibitor, Vistusertib, Combined With Anastrozole in Patients With Hormone Receptor-Positive Recurrent or Metastatic Endometrial Cancer: The VICTORIA Multicenter, Open-label, Phase 1/2 Randomized Clinical Trial.
Topics: Aged; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Breast Neoplasms; End | 2022 |
Phase 2 study of anastrozole in patients with estrogen receptor/progesterone receptor positive recurrent low-grade endometrial stromal sarcomas: The PARAGON trial (ANZGOG 0903).
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Endometrial Neoplasms; End | 2021 |
Phase 2 study of anastrozole in patients with estrogen receptor/progesterone receptor positive recurrent low-grade endometrial stromal sarcomas: The PARAGON trial (ANZGOG 0903).
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Endometrial Neoplasms; End | 2021 |
Phase 2 study of anastrozole in recurrent estrogen (ER)/progesterone (PR) positive endometrial cancer: The PARAGON trial - ANZGOG 0903.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Endometrial Neoplasms; Female; Humans; Immunohistochemi | 2019 |
Phase 2 study of anastrozole in recurrent estrogen (ER)/progesterone (PR) positive endometrial cancer: The PARAGON trial - ANZGOG 0903.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Endometrial Neoplasms; Female; Humans; Immunohistochemi | 2019 |
Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: long term results of the Italian Tamoxifen Anastrozole trial.
Topics: Adult; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Disease-Free Survival; | 2013 |
Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: long term results of the Italian Tamoxifen Anastrozole trial.
Topics: Adult; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Disease-Free Survival; | 2013 |
Neoadjuvant treatment of endometrial cancer using anastrozole: a randomised pilot study.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; | 2013 |
Neoadjuvant treatment of endometrial cancer using anastrozole: a randomised pilot study.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; | 2013 |
The ATAC ('Arimidex', Tamoxifen, Alone or in Combination) adjuvant breast cancer trial: first results of the endometrial sub-protocol following 2 years of treatment.
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvan | 2006 |
The ATAC ('Arimidex', Tamoxifen, Alone or in Combination) adjuvant breast cancer trial: first results of the endometrial sub-protocol following 2 years of treatment.
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvan | 2006 |
A phase II trial of anastrozole in advanced recurrent or persistent endometrial carcinoma: a Gynecologic Oncology Group study.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Carcino | 2000 |
A phase II trial of anastrozole in advanced recurrent or persistent endometrial carcinoma: a Gynecologic Oncology Group study.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Carcino | 2000 |
17 other studies available for anastrozole and Endometrial Neoplasms
| Article | Year |
|---|---|
Combination Vistusertib and Anastrozole Shows Benefit in Endometrial Cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Benzamides; Breast Neoplasms; Endometrial Neoplasms; F | 2022 |
Combination Vistusertib and Anastrozole Shows Benefit in Endometrial Cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Benzamides; Breast Neoplasms; Endometrial Neoplasms; F | 2022 |
Ribosome biogenesis-based predictive biomarkers in endocrine therapy (Anastrozole) combined with mTOR inhibitor (Vistusertib) in endometrial cancer: translational study from the VICTORIA trial in collaboration with the GINECO group.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Biomarkers; Breast Neoplasms; En | 2023 |
Ribosome biogenesis-based predictive biomarkers in endocrine therapy (Anastrozole) combined with mTOR inhibitor (Vistusertib) in endometrial cancer: translational study from the VICTORIA trial in collaboration with the GINECO group.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Biomarkers; Breast Neoplasms; En | 2023 |
Palliative treatment of endometrial cancer: what is the role of anastrozole in elderly women?
Topics: Aged; Aged, 80 and over; Anastrozole; Endometrial Neoplasms; Female; Humans; Nitriles; Palliative Ca | 2021 |
Palliative treatment of endometrial cancer: what is the role of anastrozole in elderly women?
Topics: Aged; Aged, 80 and over; Anastrozole; Endometrial Neoplasms; Female; Humans; Nitriles; Palliative Ca | 2021 |
Two cases of endometrial cancer arising from adenomyosis during aromatase inhibitors therapy after mastectomy.
Topics: Adenocarcinoma; Adenomyosis; Anastrozole; Aromatase Inhibitors; Breast Neoplasms; Endometrial Neopla | 2017 |
Two cases of endometrial cancer arising from adenomyosis during aromatase inhibitors therapy after mastectomy.
Topics: Adenocarcinoma; Adenomyosis; Anastrozole; Aromatase Inhibitors; Breast Neoplasms; Endometrial Neopla | 2017 |
Long-term survival in low-grade endometrial stromal sarcoma with childbirth and multidisciplinary treatment: a case report.
Topics: Adult; Anastrozole; Antineoplastic Agents, Hormonal; Biopsy; Endometrial Neoplasms; Female; Humans; | 2015 |
Long-term survival in low-grade endometrial stromal sarcoma with childbirth and multidisciplinary treatment: a case report.
Topics: Adult; Anastrozole; Antineoplastic Agents, Hormonal; Biopsy; Endometrial Neoplasms; Female; Humans; | 2015 |
Recurrent endometrial carcinoma regression with the use of the aromatase inhibitor anastrozole.
Topics: Adenocarcinoma; Anastrozole; Aromatase Inhibitors; Endometrial Neoplasms; Female; Humans; Immunohist | 2008 |
Recurrent endometrial carcinoma regression with the use of the aromatase inhibitor anastrozole.
Topics: Adenocarcinoma; Anastrozole; Aromatase Inhibitors; Endometrial Neoplasms; Female; Humans; Immunohist | 2008 |
Sustained effect of the aromatase inhibitors anastrozole and letrozole on endometrial thickness in patients with endometrial hyperplasia and endometrial carcinoma.
Topics: Aged; Anastrozole; Antineoplastic Agents; Aromatase Inhibitors; Carcinoma; Disease Progression; Endo | 2009 |
Sustained effect of the aromatase inhibitors anastrozole and letrozole on endometrial thickness in patients with endometrial hyperplasia and endometrial carcinoma.
Topics: Aged; Anastrozole; Antineoplastic Agents; Aromatase Inhibitors; Carcinoma; Disease Progression; Endo | 2009 |
[Criteria for evaluating the effectiveness of aromatase inhibitors in the neoadjuvant treatment of patients with endometrial carcinoma].
Topics: Adult; Aged; Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase; Aromatase Inhibitors; Bi | 2009 |
[Criteria for evaluating the effectiveness of aromatase inhibitors in the neoadjuvant treatment of patients with endometrial carcinoma].
Topics: Adult; Aged; Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase; Aromatase Inhibitors; Bi | 2009 |
Aromatase inhibitor anastrozole as a second-line hormonal treatment to a recurrent low-grade endometrial stromal sarcoma: a case report.
Topics: Adult; Anastrozole; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; En | 2011 |
Aromatase inhibitor anastrozole as a second-line hormonal treatment to a recurrent low-grade endometrial stromal sarcoma: a case report.
Topics: Adult; Anastrozole; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; En | 2011 |
[Endometrial stromal sarcoma: complete response to therapy with aromatase-inhibitor, anastrozole].
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Endometrial Neoplasms; Fem | 2010 |
[Endometrial stromal sarcoma: complete response to therapy with aromatase-inhibitor, anastrozole].
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Endometrial Neoplasms; Fem | 2010 |
[Effectiveness of aromatase inhibitors in comparison with metformin for neoadjuvant treatment in patients with endometrial cancer].
Topics: Adult; Aged; Anastrozole; Androstadienes; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Ar | 2011 |
[Effectiveness of aromatase inhibitors in comparison with metformin for neoadjuvant treatment in patients with endometrial cancer].
Topics: Adult; Aged; Anastrozole; Androstadienes; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Ar | 2011 |
Recurrence of prolactin-producing endometrial stromal sarcoma with sex-cord stromal component treated with progestin and aromatase inhibitor.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromat | 2004 |
Recurrence of prolactin-producing endometrial stromal sarcoma with sex-cord stromal component treated with progestin and aromatase inhibitor.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromat | 2004 |
Anastrozole, an aromatase inhibitor, and medroxyprogesterone acetate therapy in premenopausal obese women with endometrial cancer: a report of two cases successfully treated without hysterectomy.
Topics: Adult; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Endometria | 2004 |
Anastrozole, an aromatase inhibitor, and medroxyprogesterone acetate therapy in premenopausal obese women with endometrial cancer: a report of two cases successfully treated without hysterectomy.
Topics: Adult; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Endometria | 2004 |
Durable response of metastatic endometrial carcinoma to treatment with fulvestrant (Faslodex) after prior progestin and anastrozole therapy.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Endometrial Neoplasms; Estradiol; Female; Fulves | 2006 |
Durable response of metastatic endometrial carcinoma to treatment with fulvestrant (Faslodex) after prior progestin and anastrozole therapy.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Endometrial Neoplasms; Estradiol; Female; Fulves | 2006 |
Lobular carcinoma of the breast metastatic to the uterus in a patient under adjuvant anastrozole therapy.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Carcinoma, Duc | 2006 |
Lobular carcinoma of the breast metastatic to the uterus in a patient under adjuvant anastrozole therapy.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Carcinoma, Duc | 2006 |
Long-term disease-free survival after hormonal therapy of a patient with recurrent low grade endometrial stromal sarcoma: a case report.
Topics: Adult; Anastrozole; Antineoplastic Agents, Hormonal; Combined Modality Therapy; Disease-Free Surviva | 2009 |
Long-term disease-free survival after hormonal therapy of a patient with recurrent low grade endometrial stromal sarcoma: a case report.
Topics: Adult; Anastrozole; Antineoplastic Agents, Hormonal; Combined Modality Therapy; Disease-Free Surviva | 2009 |
Preclinical studies using the intratumoral aromatase model for postmenopausal breast cancer.
Topics: Anastrozole; Animals; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocol | 1998 |
Preclinical studies using the intratumoral aromatase model for postmenopausal breast cancer.
Topics: Anastrozole; Animals; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocol | 1998 |